Anzeige
Meldung des Tages: 307 Meter Gold: Dieser Treffer könnte diese Goldaktie jetzt neu bewerten

Neurocrine Biosciences Aktie News

Aktie
WKN:  900964 ISIN:  US64125C1099 US-Symbol:  NBIX Branche:  Pharmazeutika Land:  USA
137,95 $
+3,29 $
+2,44%
115,75 € 29.01.26
Depot/Watchlist
Marktkapitalisierung *
12,30 Mrd. €
Streubesitz
-
KGV
20,38
neu: Nachhaltigkeits-Score
40 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,42: MM1ZUD
Werbung

Neurocrine Biosciences News

30.07.25 - PR Newswire
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results PR Newswire
15.07.25 - PR Newswire
Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition
Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition PR Newswire
15.07.25 - PR Newswire
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid ...
14.07.25 - PR Newswire
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-​Related Effects of Glucocorticoid Treatment at the 2025 ...
14.07.25 - PR Newswire
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025 PR Newswire
09.07.25 - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results PR Newswire
30.06.25 - PR Newswire
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-​Acting Corticotropin-​Releasing Factor Type 1 Receptor Antagonist PR Newswire
27.06.25 - PR Newswire
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) ...
20.06.25 - PR Newswire
Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
Neurocrine Biosciences Presents New Data Showing Significant Patient-​Reported Improvements in Health-​Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older ...
09.06.25 - PR Newswire
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer PR Newswire
02.06.25 - PR Newswire
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
Neurocrine Biosciences Presents Patient-​Reported Outcomes from KINECT-​PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of ...
16.05.25 - PR Newswire
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
Neurocrine Biosciences to Present Wide-​Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting PR Newswire
16.05.25 - PR Newswire
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia PR ...
15.05.25 - PR Newswire
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal ...
14.05.25 - PR Newswire
Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal ...
08.05.25 - PR Newswire
Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing ...
06.05.25 - PR Newswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May PR Newswire
06.05.25 - PR Newswire
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia PR Newswire
05.05.25 - PR Newswire
Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance
Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance PR Newswire
05.05.25 - PR Newswire
Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia
Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia PR Newswire

Newssuche

Videos

newspaper
29.01.26 -2,51%
Rekordjagd bei Gold! Februar Ausblick & Forecast
Ab 2.2. (Montag) börsentäglich um 18 Uhr FEIERABEND-​TRADING. Echte Trades, strategiebasiert, ... Mehr »